

PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Orkambi

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

	Prescriber Name:	
Patient Name:	Supervising Physician:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable)	:
Drug Name and Strength:		
Directions / SIG:		
Please attach any pertinent medical history or information following que	for this patient that may support a estions and sign.	pproval. Please answer the
Q1. What diagnosis is this drug being prescribed for?		
Cystic Fibrosis	Other (Please Specify)	
Q2. Please provide ICD code(s) for diagnosis		
Q3. Please provide most recent chart note, labs, genotype for the pharmacist and medical director reviewing the requirements are met.		-
Q4. Is patient a NEW START to Orkambi therapy?		
Yes	☐ No - specify start date	
Q5. Does patient have a confirmed homozygous F508del r	nutation on the CFTR gene using	an FDA-approved test?
Yes	☐ No	
Q6. Please select all that apply regarding labs and provide	documentation:	
☐ AST/ALT < 5 x ULN		



PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Orkambi

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	Prescriber Name: Supervising Physician:	
☐ AST/ALT < 3 x ULN if bilirubin is > 2 x ULN ☐ None of the above		
Q7. If the patient is less than 18 years of age, has patient becam(s) to check for lens opacities and cataracts? Yes No N/A (Patient >18 years)	nad a baseline and, if applicable, follow up ophthalmic	
Q8. If the patient is a female of child-bearing age, is a non-hormonal form of contraception being used?		
☐ Yes ☐ No	□ N/A	
Q9. Will the patient be taking any of the following medications along with Orkambi? (Select all that apply) Kalydeco Symdeco Strong CYP3A4 inducers (e.g. barbiturates, carbamazepine, efavirenz, glucocorticoids, modafinil, nevirapine, oxcarbamazepine, phenobarbital, phenytoin, pioglitazone, rifabutin, St. John's Wort) None of the Above		
Q10. If request is for CONTINUATION of therapy, is patient's FEV1 stable or has it improved since initiation of Orkambi therapy?		
☐ Yes	□ No	
Q11. If request is for CONTINUATION of therapy, does patient have a documented clinical improvement since initiation of Orkambi therapy?		
Yes	□ No	
Q12. Additional Comments		



PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Orkambi

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name: Supervising Physician:
Prescriber Signature	Date
□ Expedited/Urgent - By checking this box and signing a	bove, I certify that applying the standard review timeframe may

seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

Lack of the necessary documentation may result in a medical necessity denial. Requesting providers may speak to a SWHP pharmacist or medical director at 1-800-728-7947 regarding the case to have an opportunity to help impact the decision on a request before coverage has been decided.

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document